U.S., Feb. 21 -- ClinicalTrials.gov registry received information related to the study (NCT06838338) titled 'JAB-21822 Combined With Chemotherapy in Second-line KRAS G12C CRC' on Sept. 25, 2024.
Brief Summary: KRAS is a common genetic mutation in tumors, and CRC is one of the tumors with a high KRAS mutation rate. The anti-tumor activity of KRAS G12C inhibitors combined with anti-EGFR anti-bodies have been proven in patients with advanced colorectal cancer, and one of them was approved for patients who have previously received standard treatment. However, Chinese patients still do not have access to these drugs. This study is to determine the efficacy and safety of KRAS G12C inhibitor JAB-21822 in combination with the second-line standard ...